Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose.

Suppr

超能文献

作者信息

Pavithran Keechilat, Thomas Mathew

出版信息

Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):288-9. doi: 10.4103/0378-6323.16628.

DOI:10.4103/0378-6323.16628

PMID:16394445

Abstract

摘要

相似文献

Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose.

Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):288-9. doi: 10.4103/0378-6323.16628.

Sti571-induced Stevens-Johnson Syndrome.

Br J Haematol. 2002 Oct;119(1):274-5. doi: 10.1046/j.1365-2141.2002.37133.x.

Imatinib-induced Stevens-Johnsons syndrome.

BMJ Case Rep. 2013 Jan 23;2013:bcr2012007926. doi: 10.1136/bcr-2012-007926.

Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.

Ann Hematol. 2007 Jul;86(7):537-8. doi: 10.1007/s00277-007-0265-y. Epub 2007 Feb 8.

Stevens-Johnson syndrome after treatment with STI571: a case report.

Br J Haematol. 2002 Jun;117(3):620-2. doi: 10.1046/j.1365-2141.2002.03499.x.

Imatinib mesylate induced immune thrombocytopenia.

Leuk Lymphoma. 2007 Nov;48(11):2261-3. doi: 10.1080/10428190701615934.

Imatinib mesylate: a new pill for chronic myelogenous leukemia.

Cancer Pract. 2001 Sep-Oct;9(5):263-5. doi: 10.1046/j.1523-5394.2001.95003.x.

Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.

Ann Oncol. 2002 Nov;13(11):1833-4. doi: 10.1093/annonc/mdf304.

Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.

Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.

Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.

Br J Haematol. 2003 Mar;120(6):1091-2. doi: 10.1046/j.1365-2141.2003.04208_3.x.

引用本文的文献

Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy.

J Inflamm Res. 2024 Apr 17;17:2337-2351. doi: 10.2147/JIR.S454673. eCollection 2024.

Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs-An Overview.

Cancers (Basel). 2023 Feb 14;15(4):1208. doi: 10.3390/cancers15041208.

Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Oncol Rep. 2021 Mar;45(3):891-898. doi: 10.3892/or.2020.7911. Epub 2020 Dec 24.

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Cancer Manag Res. 2018 May 17;10:1259-1273. doi: 10.2147/CMAR.S163391. eCollection 2018.

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

J Immunol Res. 2018 Jan 17;2018:5376476. doi: 10.1155/2018/5376476. eCollection 2018.

A rare case of imatinib-induced erythroderma.

Indian J Pharmacol. 2013 Nov-Dec;45(6):634-5. doi: 10.4103/0253-7613.121386.

Life-threatening dermatologic adverse events in oncology.

Anticancer Drugs. 2014 Feb;25(2):225-34. doi: 10.1097/CAD.0000000000000032.

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Ther Clin Risk Manag. 2008 Feb;4(1):163-87.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose.

Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):288-9. doi: 10.4103/0378-6323.16628.

Sti571-induced Stevens-Johnson Syndrome.

Br J Haematol. 2002 Oct;119(1):274-5. doi: 10.1046/j.1365-2141.2002.37133.x.

Imatinib-induced Stevens-Johnsons syndrome.

BMJ Case Rep. 2013 Jan 23;2013:bcr2012007926. doi: 10.1136/bcr-2012-007926.

Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.

Ann Hematol. 2007 Jul;86(7):537-8. doi: 10.1007/s00277-007-0265-y. Epub 2007 Feb 8.

Stevens-Johnson syndrome after treatment with STI571: a case report.

Br J Haematol. 2002 Jun;117(3):620-2. doi: 10.1046/j.1365-2141.2002.03499.x.

Imatinib mesylate induced immune thrombocytopenia.

Leuk Lymphoma. 2007 Nov;48(11):2261-3. doi: 10.1080/10428190701615934.

Imatinib mesylate: a new pill for chronic myelogenous leukemia.

Cancer Pract. 2001 Sep-Oct;9(5):263-5. doi: 10.1046/j.1523-5394.2001.95003.x.

Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.

Ann Oncol. 2002 Nov;13(11):1833-4. doi: 10.1093/annonc/mdf304.

Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.

Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.

Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.

Br J Haematol. 2003 Mar;120(6):1091-2. doi: 10.1046/j.1365-2141.2003.04208_3.x.

引用本文的文献

Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy.

J Inflamm Res. 2024 Apr 17;17:2337-2351. doi: 10.2147/JIR.S454673. eCollection 2024.

Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs-An Overview.

Cancers (Basel). 2023 Feb 14;15(4):1208. doi: 10.3390/cancers15041208.

Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Oncol Rep. 2021 Mar;45(3):891-898. doi: 10.3892/or.2020.7911. Epub 2020 Dec 24.

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Cancer Manag Res. 2018 May 17;10:1259-1273. doi: 10.2147/CMAR.S163391. eCollection 2018.

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

J Immunol Res. 2018 Jan 17;2018:5376476. doi: 10.1155/2018/5376476. eCollection 2018.

A rare case of imatinib-induced erythroderma.

Indian J Pharmacol. 2013 Nov-Dec;45(6):634-5. doi: 10.4103/0253-7613.121386.

Life-threatening dermatologic adverse events in oncology.

Anticancer Drugs. 2014 Feb;25(2):225-34. doi: 10.1097/CAD.0000000000000032.

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Ther Clin Risk Manag. 2008 Feb;4(1):163-87.